Hot on heels of a pos­i­tive PhI­II, Abl­ynx files $150M IPO; Shire sues Al­ler­gan over dry eye drug ri­val­ry

→ Af­ter watch­ing its Eu­ro­pean share price surge {$ABLX BB} yes­ter­day on pos­i­tive Phase III da­ta, Abl­ynx feels it’s per­fect tim­ing for an IPO on Nas­daq. The Bel­gian biotech is look­ing to raise around $150 mil­lion at a time a grow­ing num­ber of Eu­ro­pean biotechs have been find­ing a warm wel­come on the ex­change. The group is push­ing a new drug for ac­quired throm­bot­ic throm­bo­cy­topenic pur­pu­ra, or aTTP.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.